Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Colorectal Neoplasms 38Pancreatic Neoplasms 16Colonic Neoplasms 12Rectal Neoplasms 11Stomach Neoplasms 9Neoplasms 9Neuroblastoma 8Small Cell Lung Carcinoma 7Rhabdomyosarcoma 7Neoplasm Metastasis 7Glioblastoma 7Sarcoma, Ewing 6Gastrointestinal Neoplasms 6Central Nervous System Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Glioma 5Sarcoma 4Brain Neoplasms 4Medulloblastoma 3Intestinal Neoplasms 3Gliosarcoma 3Gastrointestinal Diseases 3Esophageal Neoplasms 3Digestive System Neoplasms 3Digestive System Diseases 3Astrocytoma 3Advanced Solid Tumors 3Recurrence 2Rectal Diseases 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2

Interventions

Radiotherapy 2surufatinib 1sodium thiosulfate 1poly ICLC 1plerixafor 1adavosertib 1Vaccines 1Temozolomide 1Radiation 1Melphalan 1Mannitol 1Irinotecan 1Eflornithine 1Decitabine 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neuroectodermal Tumors, Primitive × Irinotecan × Clear all
NCT02095132 2023-09-26

Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Completed
76 enrolled 25 charts
CNSSarcoma

Medulloblastoma, Neuroblastoma, Pinealoma, Rhabdomyosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡